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Dysregulation of melatonin metabolism in chronic renal
insufficiency: Role of erythropoietin-deficiency anemia
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Dysregulation of melatonin metabolism in chronic renal insufficiency:
Role of erythropoietin-deficiency anemia. Chronic renal failure (CRF) is
associated with a variety of neurological and endocrine disorders. In this
study, we examined the effect of CRF and the associated anemia on
circadian variation of pineal hormone, melatonin. Animals were studied
six weeks after 5/6 nephrectomy (CRF group, N = 26) or sham operation
(control group, N = 28). A group of erythropoietin-treated CRF animals(CRF/EPO, N 6) was included to discern the possible role of EPO-
deficiency anemia. Compared with the normal control group, the CRF
group showed a marked attenuation of the nocturnal surge in serum
melatonin concentration. In addition, pineal gland melatonin content
measured after a 12-hour dark cycle (s 2 lux) was significantly depressed
in the CRF group when compared to that obtained in the control group.
However, the CRF animals exhibited appropriate suppression of serum
concentration and pineal tissue melatonin content in response to bright
light ( 2500 lux). Administration of EPO led to correction of the CRF
anemia and a marked improvement of the defective nocturnal rhythm of
serum melatonin. Based on our results, experimental CRF is associated
with a marked attenuation of the normal nocturnal surge of serum
melatonin concentration. Regular EPO administration results in the
correction of anemia and substantial reversal of this abnormality suggest-
ing the partial role of EPO deficiency. The possible role of melatonin
dysregulation in the pathophysiology of CRF and the potential value of
melatonin supplementation in this condition is uncertain and awaits future
investigations.
The pineal hormone, melatonin, is involved in synchronization
of certain physiological functions with the daily changes in the
external environment [I]. Accordingly, melatonin plays an impor-
tant role in regulation of sleep pattern and modulation of
hypothalamic, pituitary, gonadal, adrenal and thyroid functions as
well as insulin sensitivity and cellular and humoral immunity
[2—13]. In addition, melatonin is a highly potent, endogenous
antioxidant [14, 15]. Abnormal levels of melatonin are frequently
found in various affective disorders. For instance, melatonin level
is elevated in seasonal affective disorders and reduced in melan-
cholia [16, 17].
Patients and animals with chronic renal failure (CRF) exhibit a
variety of endocrine abnormalities including hypothalamic-pitu-
itary dysregulation, gonadal dysfunction, thyroid disorders, and
altered endorphin, vasopressin, catecholamine and insulin metab-
olisms [18—31]. In addition, sexual dysfunction, sleep disorders,
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mental depression and impaired cellular immunity are common in
this population [32—36]. Accordingly, several clinical and bio-
chemical features of CRF seem to resemble those of altered
melatonin metabolism. In fact, circadian rhythm of plasma mela-
tonin has been recently shown to be abnormal in patients with
end-stage renal disease [37, 38].
Treatment of CRF-associated anemia with erythropoietin
(EPO) has been shown to ameliorate certain neurologic and
endocrine abnormalities of uremia [39—43]. We, therefore, hy-
pothesized that correction of CRF anemia with EPO may also
ameliorate CRF-associated melatonin dysregulation. To this end,
we undertook the present study to explore the effect of chronic
renal insufficiency and the associated EPO-deficiency anemia on
melatonin metabolism in rats with CRF induced by 5/6 nephrec-
tomy.
Methods
Male Sprague-Dawley rats (Charles River Inc., Wilmington,
MA, USA) weighing 250 to 350 g were randomized into chronic
renal failure (CRF, N = 26) and sham-operated control (N = 28)
groups. In an attempt to discern the possible effect of EPO-
deficiency anemia of CRF, a subgroup of EPO-treated CRF
animals (CRF/EPO group, N = 6) was also included. Animals in
the CRF groups underwent left nephrectomy and 2/3 right
nephrectomy through a dorsal incision. The procedure was car-
ried out under general anesthesia using sodium pentobarbital 50
mg/kg, i.p. Strict hemostasis and aseptic measures were observed.
The control group underwent sham operation without nephrec-
tomy. The animals were observed for the ensuing six-week period
during which body wt and tail arterial blood pressure were
monitored using a rat tail sphygmomanometer (Harvard Appara-
tus, South Natick, MA, USA). In addition, serum creatinine,
creatinine clearance, and hematocrit were determined at the end
of week 6 using standard laboratory techniques. Animals were
housed in a temperature-controlled, light regulated space with
12-hour day (500 lux) and night (< 2 lux) cycles and fed regular
Rat Chow (Newco Industry, Fontana, CA, USA) ad libitum.
Individual metabolic cages were used for urine collections. The
animals assigned to the CRF/EPO group were given i.p. injections
of recombinant EPO (Epogen-a; Amgen Inc., Thousand Oaks,
CA, USA), 150 U/kg twice weekly. The circadian rhythm of serum
melatonin was studied in blood samples obtained at 7 p.m.,
11 p.m., 1 a.m., 5 a.m. and 7 a.m.
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Table 1. Body weight, systolic blood pressure, hematocrit and
creatinine clearance (Ccr) in placebo- (CRF) and EPO- (CRF/EPO)
treated animals with chronic renal failure and the normal control group
Body
weight
g
Blood
pressure
mm Hg
Hematocrit
%
C.
mi/mm
CRF 408 7 158 7 39.5 1.1 0.91 0.1
CRF/EPO 407 8 180 7 50.5 1.9 0.76 0.20
Control 445 5 101 5U 46.9 0.5 2.38 0.12
Data are means SEM obtained from 16 rats in the CRF and control
groups each and 6 rats from the CRF/EPO group.
P < 0.001 (ANOVA)
Effect of light intensity on serum and pineal melatonin levels
In an attempt to examine the integrity of the optical pathway of
melatonin regulation, the animals were studied after periods of
dark and bright light cycles. To this end, animals were placed in
light-controlled chambers where they were exposed to either dark
(<2 lux) or bright light ( 2500 lux) conditions for 12-hour cycles
beginning at 6 p.m. and ending at 6 am. Immediately after the
conclusion of the dark and light cycles, blood samples were
obtained and animals were killed by decapitation. Pineal tissue
was then removed and immediately placed in liquid nitrogen. The
tissue was subsequently transferred to the assay buffer where it
was homogenized by sonication while on ice. The homogenate was
then centrifuged at 2000 x g for 20 minutes, and the supernatant
removed for melatonin determination.
Melatonin assays
Melatonin concentration in serum and pineal tissue extract was
measured by radioimmunoassay using a monospecific rabbit anti-
melatonin antibody and '251-melatonin as described previously
[4I. On each occasion a standard curve was constructed using
multiple dilutions of the standard solution. Melatonin concentra-
tion in the test sample was determined by interpolation of the data
into the standard curve. The intra-assay coefficients of variation
for melatonin assay was 3.3%. The supplies for the melatonin
assay were purchased from Nichols Institute Inc. (San Juan
Capistrano, CA, USA).
Data presentation and analysis
Data are presented as mean SEM. Analysis of variance
(ANOVA) and appropriate t-tests were employed in evaluation of
the data. P values equal to or less than 0.05 were considered
significant.
Results
General
The body weight, systolic blood pressure, creatinine clearance
and hematocrit measurements obtained in the three groups are
given in Table 1. At the time of the study, body weights in the
CRF and CRF/EPO groups were comparable with one another
and significantly lower than that found in the normal control
group. As expected, the CRF and CRF/EPO groups had a
significant elevation of arterial blood pressure when compared to
the normal control group. Likewise, the CRF and CRFIEPO
groups exhibited a significant elevation of serum creatinine and a
significant reduction in creatinine clearance relative to the corre-
sponding values in the control animals. As expected, the CRF
Fig. 1. A. Changes in plasma melatonin levels during the night time (19.00
to 07.00) in twelve chronic renal failure (CRF, "), six eythropoietin-
treated CRF (CRF/EPO, ----), and twelve control (—) rats. Blood samples
were collected every two hours. Each data point represents the mean value
and bars denote SEM. B. Area under the plasma concentration time
curve in the study groups. < 0.05 versus other groups. #p < 0.05 versus
CRF group. No significant difference was found between values obtained
in the CRF/EPO group with those found in the normal control group.
group showed a significant reduction in hematocrit which was
prevented with EPO therapy in the CRF/EPO group.
Nocturnal variation of serum melatonin
Serum melatonin concentrations obtained between the hours of
7 p.m. and 7 a.m. are depicted in Figure 1. As expected, animals
in the control group showed a steady rise in serum melatonin
concentration reaching a peak at 3 a.m. followed by a gradual
decline toward baseline values thereafter. In comparison with the
control group, the CRF group showed a consistently lower serum
melatonin concentration during the study period. The observed
attenuation of the nocturnal surge in serum melatonin was
partially ameliorated with the correction of EPO-deficiency ane-
mia in the CRFIEPO group. The area under the melatonin
concentration time curves in the control rats (1866 132 pg/mI
12 hr) and the CRF/EPO rats (1643 211 pg/mI 12 hr) were
significantly (P < 0.05) higher than that found in the CRF rats
(1055 105 pg/mI 12 hr). No significant difference was found
between values obtained in the CRF/EPO group with those found
in the control group.
Effect of light on serum and pineal tissue melatonin
Comparison of serum melatonin concentrations obtained at
6 a.m. after the 12-hour dark (< 2 lux) and bright light cycles
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Fig. 2. Pineal gland melatonin content obtained following a 12-hour dark
cycle ( 2 lux) and a 12-hour bright light cycle ( 2500 lw) at 6 am, in the
chronic renal failure • CRF, N = 6 in dark and N = 8 in bright light
conditions) and control (E, N = 8 in both bright light and dark conditions)
groups. Data are shown as mean SCM. *p < 0.05 versus CRF.
( 2500 lux) revealed marked suppression with bright light in the
CRF and control groups (41 8%,N= 5, in CRF, and 24 19%,
N = 4, in the normal control group). No significant difference was
found in the percent suppression of serum melatonin level with
bright light (relative to values obtained in the dark cycle) between
the two groups (P = NS). Likewise, pineal gland tissue melatonin
content was equally suppressed with bright light exposure in the
two groups (64 6.6%, N = 6, in CRF; and 81 3.9%, N = 8,
in the normal control group; P < 0.05 for both groups). Mean
pineal gland melatonin content measured after the dark cycle was
significantly lower (P < 0.001) in the CRF group (3020 605
pg/gland, N = 6) than in the normal control group (4687 528
pg/gland, N = 8; Fig. 2).
Discussion
Melatonin (N-acetyl-5-methoxytryptamine) is the principal pi-
neal hormone which is produced from the essential amino acid,
tryptophan, through a number of biochemical processes [45].
These include hydroxylation and decarboxylation steps to form
serotonin which is in turn converted to N-acetylserotonin (by the
rate limiting enzyme, serotonin N-acetyltransferase [NAT] in the
presence of acetylcoenzyme-A). The latter is finally methylated by
hydroxyindol-0-methyltransferase (HIOMT) to form melatonin.
The NAT activity and hence melatonin production is regulated
by the adrenergic activation of the pineal cells. In addition,
melatonin production is modulated by the photic stimuli which
originate from the retina and are transmitted to the pineal gland
through the hypothalamic suprachiasmatic nuclei and cervical
sympathetic ganglia. Melatonin receptors are present in the cells
of various organs throughout the body indicating the hormone's
wide range of action. Normally serum and pineal concentrations
of melatonin and pineal NAT activity exhibit marked diurnal
variations. Accordingly, the corresponding values rise during the
night, reaching their peaks between midnight and 6 a.m. (approx-
imately 3 am. in rats) and fall during the day. Recent studies have
revealed a marked attenuation of the normal nocturnal and
matutinal variations of serum melatonin in patients with end-stage
renal disease [37, 38]. In the present study we found a marked
attenuation of the normal nocturnal surge of serum melatonin in
animals with CRF, confirming the earlier clinical observations
[37]. The observed attenuation of the nocturnal rise in serum
melatonin was accompanied by a parallel reduction in the pineal
gland melatonin contents (obtained following the dark cycle) in
the CRF group suggesting reduced melatonin production.
Regular EPO administration led to correction of anemia and
partial restoration of the nocturnal rise of melatonin in the
CRF/EPO group. This observation points to the possible role of
EPO deficiency in the pathogenesis of melatonin dysregulation in
CRF. The amelioration of this particular neuroendocrinological
disorder with the correction of CRF-associated EPO-deficiency
anemia is not entirely surprising. In fact, EPO therapy has been
recently shown to restore TSH response to TRH, improve FSH
response to GnRH and normalize the basal levels of growth
hormone and prolactin in patients with end-stage renal disease
[39]. Likewise, long-term EPO therapy has been reported to
modify plasma ACTH, cortisol, glucagon, pancreatic polypeptide,
renin, aldosterone and gastrin levels and raise plasma concentra-
tions of gonadal hormones, thyroxin and atrial natriuretic peptide
[40]. In addition, EPO therapy has been shown to significantly
improve the electroencephalographic abnormalities, the defective
event-related potentials, and the cognitive dysfunction in patients
with chronic renal failure [41, 42]. Therefore, amelioration of
melatonin dysregulation with EPO administration in our rats with
CRF appears to be consistent with the demonstrated effects of this
therapy on various other neuroendocrinological disorders of
uremia. The available data do not allow any conclusion as to the
mechanism(s) by which EPO replacement improves the CRF-
associated dysregulation of melatonin metabolism. Further stud-
ies are required to determine if the effect of EPO therapy is
mediated by correction of CRF anemia or represents a direct
action of the hormone on melatonin production. The latter is
particularly intriguing since the effect of EPO on blood pressure
has been convincingly shown to be independent of its hematopoi-
etic action [43]. Studies of melatonin metabolism in animals and
humans with nonrenal anemia can help to address this issue.
The attenuated nocturnal rise in serum melatonin concentra-
tion, shown in experimental CRF here and previously shown in
patients with end-stage renal disease, may be causally related to
insomnia and sleep disorders frequently present in clinical uremia.
In addition, altered melatonin metabolism may contribute to the
pathogenesis of mental depression and diminished immunity in
uremia. It is unclear if nightly melatonin administration can
restore normal nocturnal concentrations of melatonin in renal
insufficiency and, if so, whether it can favorably affect the associ-
ated sleep disorder and mental depression. Future studies are
needed to address this question.
In an attempt to examine the integrity of the optical pathway of
melatonin regulation in the CRF animals, we conducted a series
of experiments under dark and bright light conditions. These
experiments revealed an appropriate bright light-induced sup-
pression of pineal tissue and serum melatonin levels in the CRF
group indicating that the photic modulation of melatonin produc-
tion and release is intact in experimental CRF.
In conclusion, the CRF animals showed an attenuated noctur-
nal surge in serum melatonin concentration. This was associated
with a significantly lower pineal gland melatonin content suggest-
ing depressed melatonin production. Regular EPO therapy led to
correction of CRF anemia and partial restoration of normal
nocturnal melatonin rhythm suggesting the possible role of EPO-
deficiency. Experiments conducted under bright light and dark
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conditions revealed no discernible defect in the optical regulatory
pathway of melatonin production/release in CRF. Further studies
are required to determine the role of melatonin dysregulation in
the pathophysiology of CRF and the potential value, if any, of
melatonin supplementation in this condition.
Reprint requests to Nostraola D. Vaziri, M.D., Division of Nephrology,
Department of Medicine, UCI Medical Center, 101 The City Drive, Orange,
California 92668 USA.
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